Abstract Number: 1921 • ACR Convergence 2022
Association Between Knee Osteoarthritis and Health-Related Quality of Life in Persons with Type 2 Diabetes
Background/Purpose: Knee osteoarthritis (OA) and type 2 diabetes commonly co-occur due to shared risk factors. Both knee OA and type 2 diabetes negatively impact health-related…Abstract Number: 0208 • ACR Convergence 2022
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)
Background/Purpose: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in DM, as measured by CDASI-A.…Abstract Number: 1050 • ACR Convergence 2022
Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis
Background/Purpose: The prevalence of depression among patients with systemic sclerosis (SSc) is 35-65%1, yet little is known about mental health care utilization in SSc. It…Abstract Number: 1973 • ACR Convergence 2022
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
Background/Purpose: Despite treatment with strong immunosuppressive medications, more than half of patients with rheumatoid arthritis (RA) still report pain. Pain can spread from joint sites…Abstract Number: 0285 • ACR Convergence 2022
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor, is a newly approved advanced therapy for patients (pts) with rheumatoid arthritis (RA), thus real-world evidence is lacking.…Abstract Number: 1299 • ACR Convergence 2022
Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children with significant morbidity that extends into adulthood. Despite advances in effective…Abstract Number: 2066 • ACR Convergence 2022
Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population
Background/Purpose: Patients with SLE present with greater sexual dysfunction (SxD) than patients with other chronic diseases [1]. These patients tend to be younger compared to…Abstract Number: 0390 • ACR Convergence 2022
Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients
Background/Purpose: Symptomatic onset long after recovery from the acute phase of COVID-19 infection has been reported by the population. Currently, it is not known how…Abstract Number: 1336 • ACR Convergence 2022
Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are chronic diseases often causing disability in patients, associated with both disease activity and damage accrual. These conditions might reduce…Abstract Number: 2070 • ACR Convergence 2022
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the…Abstract Number: 0395 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…Abstract Number: 1344 • ACR Convergence 2022
Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue
Background/Purpose: Patient Reported Outcomes (PROs) can be assessed by self-administered questionnaires and can lead to better decision-making by physicians. The aim of this study was…Abstract Number: 2094 • ACR Convergence 2022
Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)
Background/Purpose: To examine and compare baseline predictors of improvement in HRQoL in adults with systemic lupus erythematosus (SLE) with disease onset occurring before age 24…Abstract Number: 0409 • ACR Convergence 2022
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…Abstract Number: 1345 • ACR Convergence 2022
Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?
Background/Purpose: The SARS-CoV-2 pandemic is a worldwide mental health crisis. We evaluated perceived stress in patients seeking care for musculoskeletal conditions, and explored associations with…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 25
- Next Page »